Bank Julius Baer & Co
FPRX

Bank Julius Baer & Co’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bank Julius Baer & Co’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-430
Closed -$2K – 874
2020
Q3 		$2K Hold
430
– – ﹤0.01% 722
2020
Q2 		$3K Sell
430
-8
-2% -$33 ﹤0.01% 649
2020
Q1 		$1K Buy
+438
New +$1.86K ﹤0.01% 636

Other funds holding FPRX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank Julius Baer & Co's FPRX Position: Q4 2020 in Review

Bank Julius Baer & Co sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 430 shares — an estimated $2K sold.

Bank Julius Baer & Co first reported a position in FPRX in Q1 2020 and held it in 3 quarters. The position peaked at $3K in Q2 2020. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

  • Bank Julius Baer & Co reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Bank Julius Baer & Co sold 430 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $2K.
  • Bank Julius Baer & Co first reported a position in Five Prime Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's Five Prime Therapeutics, Inc. position peaked at $3K in Q2 2020.
  • 125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on Bank Julius Baer & Co's 13F filing for Q4 2020, filed 12 Feb 2021.